急性心肌梗死合并心源性休克的侵入性管理:AHA科学声明
该科学声明概述了急性心肌梗死合并心源性休克(AMICS)的当代侵入性管理最佳实践。内容涵盖冠状动脉血运重建、机械循环支持(MCS)的使用以及合并心脏骤停患者的特殊考量。声明指出,尽管早期血运重建可改善生存,但死亡率已趋于平稳,且MCS的获益尚未在随机临床试验中确立。
要点
- 早期血运重建是AMICS生存获益的关键,但死亡率改善已进入平台期。
- MCS在AMICS中的生存获益尚未在随机临床试验中证实,使用时机和模式存在差异。
- 建议建立心源性休克中心并采用标准化方案管理AMICS,包括MCS的应用。
核心结论
- AMICS的侵入性管理需结合早期血运重建、合理使用MCS及标准化方案,但MCS的生存获益仍待随机试验验证。
研究设计与样本
- 美国心脏协会(AHA)科学声明,基于现有证据和专家共识总结AMICS的侵入性管理最佳实践。
主要发现
- SHOCK试验证实早期血运重建可改善AMICS患者生存,但此后死亡率改善停滞。
- 近期SCAI分类方案有助于区分心源性休克的广泛表现。
- 部分心源性休克中心实施标准化方案(包括MCS)后报告了有希望的结果。
- MCS在AMICS中的生存获益尚未在随机临床试验中确立。
关键数值与推荐
- 声明推荐建立心源性休克中心,使用标准化方案进行诊断和管理,包括MCS设备。
- 声明概述了AMICS的当代介入管理最佳实践,包括冠状动脉血运重建、MCS使用及心脏骤停患者的特殊考量。
临床怎么用
- 临床应遵循标准化方案对AMICS患者进行侵入性管理,包括早期血运重建和合理应用MCS。
- 需注意MCS使用时机和模式在不同医疗系统间存在差异,应结合患者具体情况决策。
局限性
- MCS在AMICS中的生存获益尚未在随机临床试验中证实。
- 不同医疗系统间导管室实践模式存在差异,MCS使用和时机不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiogenic shock (CS) remains the most common cause of mortality in patients with acute myocardial infarction. The SHOCK trial (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) demonstrated a survival benefit with early revascularization in patients with CS complicating acute myocardial infarction (AMICS) 20 years ago. After an initial improvement in mortality related to revascularization, mortality rates have plateaued. A recent Society of Coronary Angiography and Interventions classification scheme was developed to address the wide range of CS presentations. In addition, a recent scientific statement from the American Heart Association recommended the development of CS centers using standardized protocols for diagnosis and management of CS, including mechanical circulatory support devices (MCS). A number of CS programs have implemented various protocols for treating patients with AMICS, including the use of MCS, and have published promising results using such protocols. Despite this, practice patterns in the cardiac catheterization laboratory vary across health systems, and there are inconsistencies in the use or timing of MCS for AMICS. Furthermore, mortality benefit from MCS devices in AMICS has yet to be established in randomized clinical trials. In this article, we outline the best practices for the contemporary interventional management of AMICS, including coronary revascularization, the use of MCS, and special considerations such as the treatment of patients with AMICS with cardiac arrest.
引用
- Henry TD, Tomey MI, Tamis-Holland JE, et al. Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2021. PMID: 33657830. doi:10.1161/CIR.0000000000000959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。